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The complement system has been considered for a long time as a simple lytic cascade,
aimed to kill bacteria infecting the host organism. Nowadays, this vision has changed and
it is well accepted that complement is a complex innate immune surveillance system, play-
ing a key role in host homeostasis, inflammation, and in the defense against pathogens.
This review discusses recent advances in the understanding of the role of complement in
physiology and pathology. It starts with a description of complement contribution to the
normal physiology (homeostasis) of a healthy organism, including the silent clearance of
apoptotic cells and maintenance of cell survival. In pathology, complement can be a friend
or a foe. It acts as a friend in the defense against pathogens, by inducing opsonization
and a direct killing by C5b–9 membrane attack complex and by triggering inflammatory
responses with the anaphylatoxins C3a and C5a. Opsonization plays also a major role in
the mounting of an adaptive immune response, involving antigen presenting cells, T-, and
B-lymphocytes. Nevertheless, it can be also an enemy, when pathogens hijack comple-
ment regulators to protect themselves from the immune system. Inadequate complement
activation becomes a disease cause, as in atypical hemolytic uremic syndrome, C3
glomerulopathies, and systemic lupus erythematosus. Age-related macular degeneration
and cancer will be described as examples showing that complement contributes to a
large variety of conditions, far exceeding the classical examples of diseases associ-
ated with complement deficiencies. Finally, we discuss complement as a therapeutic
target.
Keywords: complement system, adaptive immunity, crosstalk TLR-complement, pathogen strategies for
immune evasion, complement in cancer, complement and innate immunity, complement-related diseases,
anaphylatoxins
The Complement System
Complement system represents a major part of the innate immunity. It is a cascade of soluble
proteins and membrane expressed receptors and regulators (Figure 1), which operates in plasma,
in tissues, on cell surface, and even within the cell. It is composed of more than 40 proteins, the
soluble ones being produced mainly by the liver. Complement was discovered at the end of the
nineteenth century and described as a “factor” or “principle” capable to induce bacterial lysis.
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FIGURE 1 | Complement activation. Complement system is composed of
three different pathways. CP is activated by immune complex formation on
pathogen surface and by calreticulin expressed on apoptotic cells, leading to
C1 complex association. LP recognizes mannose-terminating glycan on
pathogens leading to MBL MASP complex activation. Both induce formation
of the classical C3 convertase C4b2a. AP is permanently activated at low
level by spontaneous hydrolysis of C3 into C3(H2O). Lack of complement
inhibitor on pathogens induces alternative C3 convertase activation C3bBb.
Complement activation leads to opsonization and phagocytosis by C3b
deposition, bacterial lysis by C5b–9 complex formation and inflammation by
recruitment of immune cells, endothelial and epithelial cells activation, and
platelets activation.
After that, for a long time, complement system has been consid-
ered as a supportive part of the innate immunity and received
relatively little attention from the immunologists. Over the years,
it became clear that complement has versatile functions and that
its action extends far beyond the simple bactericidal activity. In
a healthy individual, it orchestrates the immunologically silent
clearance of host cells after their programed cell death. Com-
plement cascade is activated immediately after encountering the
pathogen. Hence, complement participates in pathogen opsoniza-
tion, tagging it for engulfment by antigen presenting cells (APC);
it plays a central role in the inflammatory process and modu-
lates the activity of T- and B-cells. After generation of pathogen-
specific antibodies, complement contributes in the clearance of
immune complexes and pathogen elimination. Studies over the
years demonstrated that complement takes part in nearly every
step of the immune reaction and that it deserves a central position
in the immunological research. Unfortunately, the lack of coher-
ence in complement proteins nomenclature and the complexity
of the enzymatic cascade render complement one of the “most
complicated and incomprehensible” parts of immunology and is
frequently avoided by students and scientists. With this review,
we aim to underline the crucial importance of complement in
physiology and pathology.
Complement in Physiology
Sampling for Foreign and Altered Cells
The main complement rule is that everything that is not specifi-
cally protected has to be attacked. Host cells carry an armamentar-
ium of “don’t attack me” molecules, which are either expressed by
the cell or recruited to the cell membrane from the plasma. There-
fore, any cell, debris, microorganism, or artificial material lacking
these molecules (and carrying  OH or  NH2 chemical groups,
which is the case of all biological andmost syntheticmaterials) will
represent an “activating surface” and will support complement
deposition, i.e., covalent binding of C3b, an activated form of the
central complement component C3. This action is provided by the
so-called alternative complement pathway, which is permanently
active and constantly probes the environment for the presence of
activating surfaces (Figure 2A). In addition, several pattern recog-
nition molecules recognize material that has to be eliminated,
such as apoptotic cells, debris, pathogens, immune complexes, and
activate the classical and lectin complement pathways (CP and LP)
(Figure 2B). All pathways converge at the point of C3 cleavage,
which results in generation of bioactive fragments C3a and C3b.
C3b binds covalently to any surface and, if it is not specifically
protected. The level of C3 deposition is increased by the so-called
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FIGURE 2 | Role of complement in physiology. (A) Protection of host
cells against complement. Complement AP is permanently activated and
deposits C3b molecules to any surface. On host cells, these C3b molecules
are rapidly inactivated by different membrane expressed or plasma
complement regulators. (B) Immunologically silent clearance of apoptotic
cells. Limited complement activation occurs on apoptotic cells. C1q
recognizes “eat-me” signals on the surface of dying cells. It serves as a
bridging molecule, facilitating the phagocytosis by dendritic cells or
macrophages. Uptake of C1q-opsinized cargo induces an anti-inflammatory
program, increased expression of immunological checkpoint molecules, and
prevents up-regulation of maturation markers. iC3b on apoptotic cells
interacts with CR3 on phagocytes and induces anti-inflammatory response.
(C) Complement in human T cell homeostasis. Cathepsin L cleaves C3
intracellularly, generating C3a and C3b. C3a binds on C3aR, expressed in
the lysosomes, and stimulates mTOR signaling pathway. This signaling is
important for the cell survival in resting state.
“amplification loop” of the alternative pathway (AP). Detailed
description of the mechanisms of activation and regulation of the
complement system are described in “Complement system part
I – molecular mechanisms of activation and regulation” (1), from
the same research topic of Frontiers in Immunology.
Briefly, in a healthy organism, the sentinel role is assured
by the permanent activity of the AP (1 and 2). A number of
complement components are produced in biologically inactive
form, which allows them to co-exist in plasma, or to be pro-
duced by the same cells, without interacting with one another
and inducing unnecessary and undesired complement activa-
tion. Complement components are activated in a cascade fashion
after a triggering event, each step of the chain reaction, resulting
in a conformational change or a cleavage of the downstream
component, which becomes activated and gains the capacity to
activate the subsequent component in the cascade. Spontaneous
hydrolysis, called tick-over, of C3 plays an important role in the
immune surveillance and AP activation (2). C3 is present in
plasma at high concentrations (~1mg/ml) and a small portion
of it undergoes spontaneous hydrolysis of a particular thioester
bond between the side chains of two aminoacids, located in
the thioester domain (TED). This hydrolysis induces a dramatic
conformational change in C3 and renders it biologically active
due to exposure of novel binding sites. In this new form – the
C3(H2O), it recruits two other plasma molecules – factor B (FB)
and factor D (FD). FD cleaves C3(H2O)-bound FB to generate an
enzymatic complex C3(H2O)Bb, called fluid phase C3 convertase.
The name convertase indicates that this enzymatic complex can
cleave (convert) a native C3 molecule into bioactive fragments
C3a (the small fragment) and C3b (the big fragment). C3a is an
anaphylatoxin – a pro-inflammatory molecule, which activates
the surrounding cells when reaching a threshold concentration.
Upon releasing the C3 ANA domain, which becomes the C3a
molecule, the remaining part C3b undergoes a dramatic con-
formational change, similar to that of C3(H2O). In the newly
generated C3b, contrary to C3(H2O), the thioester bond is not
hydrolyzed but becomes transiently exposed, allowing, for a very
short time, a covalent reaction with OH  or NH2  groups on
any molecule or cell in its immediate surroundings. If this bond
is not formed, the very short-lived nascent form is hydrolyzed
and inactivated in few milliseconds, leaving the inactivated C3b
molecule in the fluid phase. When covalently bound to a cell, C3b
has different fates depending if it is on a host cell or on a foreign
surface.
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2573
Merle et al. Complement system part II: role in immunity
Protection of the Host Cells Against Complement
Attack
The deposition of C3b is highly controlled on host cells. Host
cells express complement regulatory molecules on their surface
(membrane bound such as membrane cofactor protein, MCP,
CD46 or complement receptor 1, CR1, CD35), or recruit plasma
regulators, like factor H (FH), which bind to C3b. These pro-
teins serve as cofactors, allowing interaction with a plasma serine
protease factor I (FI), which cleaves C3b into iC3b (Figure 2A).
This results in a conformational change, which suppresses the
ability to interact with FB but exposes of novel binding sites in
the iC3b molecule, allowing it to interact with other complement
molecules. FH also blocks the binding of FB and FD to C3b, thus
preventing the formation of C3 convertases. The overall action of
all these regulators results in the prevention of complement acti-
vation on host cells. In the absence of surface regulators, such as in
the case of pathogens or other foreign surface, C3b interacts with
FB and FD, forms C3 convertases, which cleave more molecules
of C3 to C3a and C3b, thus fueling the amplification loop and
allowing full-blown complement activation and, finally, pathogen
elimination.
Immunologically Silent Phagocytosis of
Apoptotic Cells
Between these two extremes (healthy cell and pathogen) remains
the case of stressed and apoptotic host cells. The human body is
composed to a myriad of different cells, forming a highly orga-
nized system. The proliferation, differentiation, activity, and also
the death of cells in this system are tightly controlled. Programed
cell death induces major cellular modifications. During a clas-
sical cell death, the cell surface undergoes many structural and
molecular modification, leading to “eat-me” signals expression.
Phagocytes recognize these signals and execute the degradation
of apoptotic cell without mounting of an immunologic response.
Among these modifications, a major one is the expression of
phosphatidylserine (PS) on the external side of the cell membrane,
which is normally sequestered in the inner surface of the cell
membrane (3). Also, the expression level of some complement
regulators (such as MCP) can be reduced. Clearance of apop-
totic cells is critical for many physiological processes, including
development, tissue remodeling, andmaintenance of homeostasis.
The complement system plays a major role in the tolerogenic
perception of apoptosis, which is in partmediated by opsonization
with C1q and iC3b and subsequent clearance of dying cells (4,
5) (Figure 2B). C1q, which is the recognition molecule of the
CP, is produced by macrophages and dendritic cells (DCs) and
binds to a variety of ligands that can be expressed on the surface
of apoptotic cells such as PS, double stranded DNA, GAPDH, or
calreticulin (6–9). C1q has complex immune-modulatory effects
and a failure of C1q to opsonize apoptotic cells results in defective
phagocytosis by monocytes (10) and activation of the DCs (11).
Consistently, a quantitative or functional deficiency in C1q may
be related to improper apoptotic cell clearance and autoimmunity
(12, 13). Similar functions are described for mannose binding
lectin (MBL), one of the recognition molecules of the LP (14).
C1q coated apoptotic cells suppress macrophage inflamma-
tion through induction of interleukine 10 (IL-10), IL-27, IL-33,
and IL-37, inhibit inflammasome activation and increase the
expression of negative regulators ASC2 and NLRP12 (15). It has
recently been demonstrated that opsonization of apoptotic cells
by C1q induced an increase of the expression of PD-L1 and PD-
L2 and a diminution of CD40 at the surface of macrophages (16).
Similar effects are observed also on dendritic cells. Presentation
of self-antigens by DC in the presence of C1q promotes the
development of regulatory T cells (Treg) and the production of
anti-inflammatory cytokines such as TGF-b, IL-10, PGE2, IL-37,
and IL-27 and thus confers tolerance. In addition, opsonization
of the apoptotic cells with C1q induced a high expression of PD-
L2 and less CD86 on dendritic cells surface after phagocytosis.
This “polarization” by C1q-induced decrease of T helper 1 (Th1)
and Th17 and proliferation. The non-maturation of the phago-
cytes, which is showed by the expression of CD40 and CD86 on
macrophages and dendritic cells, respectively, and by the secretion
of anti-inflammatory cytokines,makes the phagocytosis immuno-
logically silent (16). Therefore, C1q is of critical importance for
the silent, non-immunogenic clearance of apoptotic cells (17)
(Figure 2B).
The inactivated fragment of the central complement com-
ponent C3–iC3b participates in the clearance of apoptotic cells
via interaction with CR3 on monocytes, macrophages, DC, and
microglial cells (18–20). iC3b opsonization and CR3-dependent
phagocytosis is accompanied by a down-regulation of the pro-
inflammatory mediator IL-12 and a lack of oxidative burst in
macrophages (21, 22) or by a reduction in the expression of
costimulatory molecules and impaired maturation of DC (23, 24).
This confers anti-inflammatory properties and supports tolero-
genic apoptotic cell clearance.
Cell Homeostasis
In the native state, different cell types secrete complement com-
ponents and generate C3a and C5a in their microenvironment,
an important fact for their viability and function. Liszewski et al.
demonstrated that C3 activation can occur continuously within
human T cells, mediated by cathepsin L (CTSL) and in a C3
convertase-independent manner (25) (Figure 2C). In resting T
cells, this C3a binds to intracellular C3aR, expressed in lysosomes,
but not on the cell surface. Intracellular C3aR signaling sustains
basal mTOR activation (25), required for homeostatic cell sur-
vival (26). Of note, C3a generated outside the cell cannot restore
the mTOR signaling in cells with inhibited CTSL, suggesting
the importance of intracellular generated C3a (25). Upon T cell
receptor (TCR) activation, C3aR is expressed on the cell surface
and contributes to the mounting of Th1 response in concert with
CD46 signaling.
Of note, the phenomenon of intracellular C3 cleavage seems to
be species specific, because it does not operate in mice. In mice,
resting T cells synthesize complement components constitutively,
complement activation occurs in theirmicroenvironment, and the
resultant C5a and C3a signaling, through the C5aR and C3aR,
participates in cell viability bymaintaining the level of phosphory-
lated AKT (PKB), a T cell activation intermediate that suppresses
apoptosis (27). In the absence or after blockade of C5aR andC3aR,
the expression of MHC class II and costimulatory-molecules is
decreased on dendritic cells (27, 28). The exact contribution to
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T cells survival of the intracellular and extracellular C3a genera-
tion and C3aR signaling is still not well defined. It is important to
note that AKT (PKB) andmTORbelong to the same signaling cas-
cade, which has anti-apoptotic, survival, and proliferation effects
(29). The intracellular complement activation is not restricted to
T cells (25), and may have an important role in the physiology of
other human cell types.
Complement as a First Line of Defense
Against Pathogens
Direct Killing
Pathogens are attacked by all complement pathways, but the
prevalence of one or another pathway depends on the exact mem-
brane composition. C3b generated by the spontaneous activation
of the AP tag all pathogens and, when no regulator is present, the
cascade and the deposition of C3b are accelerated (Figure 3A).
In addition, the pathogen-associated molecular patterns can be
recognized by the recognitionmolecules of theCP andLPC1q and
MBL or ficolins. C1q recognizes mostly charged patterns and can
bind to more than 100 different target molecules (30), including
pathogen-associated molecular patterns such as lipopolysaccha-
ride (LPS) (31) or bacterial porins (32).MBL binds to a wide range
of repeating sugar arrays normally presented by many microor-
ganisms, including mannose structures on fungal and micrococ-
cal surfaces, and N-acetylglucosamine residues in cell walls of
bacteria, in order to initiate neutralization of these organisms
(33). C1q may bind also on natural antibodies, which due to
their polyreactivity can recognize the pathogens (34). Upon target
recognition, C1q undergoes conformational change and activates
the two serine proteases C1r and C1s, associated with it in the
context of the C1 complex (35, 36). Despite the similarity between
C1 and MBL/MASP complex architectures, the mechanism of
activation of the CP and LP differ (37). In particular, the serine
proteases of the LP, MASP-1, and 2, are associated with different
MBL (or ficolin)molecules, thus requiring a juxtaposition to allow
MASP-1 from one complex to activate MASP-2 from the adjacent
complex (38, 39). However, MASP-2 alone provides about 10% to
cleave its natural substrate C4 by auto-activation (40). Activated
serine proteases of the CP and LP cleave C4 and C2 to allow
formation of theCPC3 convertase C4b2a, which cleaves C3. If this
convertase is not regulated, C3 deposition will be accelerated and
FIGURE 3 | Complement in the defense against pathogens.
(A) Complement-mediated bacterial killing. C3b is deposited on any pathogen
surfaces due to the constant activity of the AP. Since most pathogens do not
have complement regulatory molecules, C3b is not inactivated and interacts with
FB and FD to form a C3 convertase C3bBb. This enzymatic complex cleaves
more C3 molecules, resulting in pathogen opsonization with C3b. Further, the
cascade proceeds to a C5 convertase and MAC formation, contributing to
bacterial killing. (B) Complement receptors-mediated phagocytosis of C3b and
iC3b-opsonized pathogens. Extracellular stimulatory signals, which are
necessary for the CR3-mediated phagocytosis, include chemoattractants (not
only chemokines but also bacterial formylpeptides and C5a for neutrophils),
cytokines (e.g., TNF-α), and bacterial products (e.g., lipopolysaccharide).
External stimuli activate the integrin CR3, (i.e., change to a conformation with
high affinity for iC3b) by a Rap-1-mediated signaling. Stabilization of CR3
high-affinity conformation by its engagement with iC3b triggers a RhoA-mediated
signaling, which drives the actin polymerization to engulf iC3b-coated target.
Complex actin movements are then involved in the intracellular movement of the
phagosome during its maturation to the phagolysosome.
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the amplification loop will be turned on. Binding of an additional
C3b molecule in the immediate proximity, or most probably on
the C3 convertase itself, modifies the specificity of the enzyme
(41). It then starts to cleave C5, thus turning on a C5 convertase
of the classical (C4b2aC3b) or alternative (C3bBbC3b) pathway.
Cleavage of C5 gives rise to a powerful anaphylatoxin C5a and to
a C5b fragment, which initiates the terminal part of the cascade,
common for all activation pathways.
Activation of the terminal complement pathway results in
the formation of the membrane-attack complexes (MAC), which
forms large, 10 nm wide, pores in the target membrane (42).
In fact, most pathogens are able to repair MAC-induced lesions
and are resistant to complement lysis by MAC, as Gram-positive
bacteria (43). Nevertheless, some Gram-negative bacteria are
relatively sensitive to complement killing, particularly the menin-
gitis causing Neisseria species (44, 45). This is illustrated by
the susceptibility of individuals, deficient in terminal comple-
ment components as well as in properdin, to recurrent menin-
gitis. Gram-positive bacteria have a very thick cell wall, which
MAC cannot penetrate, therefore being resistant to complement-
mediated lysis. Metabolically active nucleated cells are also resis-
tant to lysis by complement (46, 47). However, increase of Ca
flux and signal transduction have been described as the result
of the insertion of multiple MAC in the membrane, inducing
either apoptosis and cell killing or leading to cell proliferation
depending on the cell type (48, 49). The molecular mechanisms
of complement activation on pathogens are reviewed in detail and
illustrated in Merle et al. (1).
Opsonization and Phagocytosis
The main role of complement in pathogen elimination is indi-
rect, namely, the deposition of complement fragments on the
surface of pathogen targets, so-called opsonization that allows
their recognition, ingestion, and destruction by phagocytic cells,
neutrophils, monocytes, and macrophages (Figure 3B). Both IgG
antibodies and C3 fragments are the classical opsonins. But com-
plement opsonization, resulting from the direct activation of the
AP on pathogens surface allows their elimination by phagocytes
before the mounting of an adaptive immune response and the
appearance of antibodies (Figure 3). Phagocytes express specific
receptors for C3 fragments, described in “Complement system
part I – molecular mechanisms of activation and regulation” (1).
CR1 is a complement componentmolecule (CCP) domain con-
taining molecule, involved in the control of C3 convertases. It is
present on erythrocytes, on phagocytes, and on kidney glomerular
podocytes and binds C3b and C4b. CR1 on erythrocytes plays
a major role in the clearance of soluble immune complexes, by
transporting them to the liver and spleen, where they are cleared
by macrophages. The binding of C3b-coated targets to phago-
cyte CR1 is not sufficient to trigger phagocytosis, but C3b–CR1
interaction enhances the FcγR-mediated phagocytosis of targets
bearing both IgG and C3b. Moreover, immune mediators that
activate phagocytes, such as fibronectin (50) or LPS (51), induce
the phagocytosis of targets opsonized with C3b only. However,
this is probably partially mediated by CR1 in that case, since
elastase, a major protease released by activated phagocytes, is able
both to degrade CR1 and to cleave C3b into iC3b, allowing then
iC3b-coated targets to be recognized by the efficient phagocytic
receptor CR3 (52).
CR3 and CR4 are specific receptors for iC3b, among C3 frag-
ments, able to induce the phagocytosis of iC3b-coated targets (53,
54). CR3 and CR4 belong to the integrin family, involved in cell
adhesion processes, due to their ability to interact, in particular,
with intercellular molecule-1 (ICAM-1), present on many cells,
including endothelial cells. Integrins are formed from two chains,
alpha and beta bearing magnesium ions necessary for their func-
tion. CR3 (also called MAC-1, αMβ2 or CD11bCD18) and CR4
(p150,95, αxβ2 or CD11cCD18) form, with LFA-1 and αDβ2,
the leukocyte-specific integrin subfamily sharing the β2 chain
(CD18). The CR3 also bear a lectin site, different from the iC3b
and ICAM-1 binding site, and able to recognize microorganism-
derived sugar ligands. If both the lectin and the iC3b-binding sites
of CR3 are engaged, the strength of the CR3-mediated phagocytic
response is enhanced (55).
CR3 is present onmonocytes and its expression is up-regulated
upon monocyte to macrophage differentiation. Resting neu-
trophils express low levels of CR3 on their surface but these
levels increase dramatically following cell activation, due to the
externalization of large intra-granular pools of receptors. CR4 is
expressed poorly onneutrophils andmonocytes, but its expression
increases upon monocyte differentiation to macrophage or to
dendritic cells.
The cellular processes involved in the phagocytosis of IgG- or
C3-opsonized targets are different. When phagocytosis is medi-
ated primarily via CR3, the reaction is slow and pathogens gently
sink into the phagocyte, by a process involving actin polymeriza-
tion dependent on the small GTPase Rho (53). By contrast, the
Fcγ receptors provide a very vigorous engulfment of IgG-coated
pathogens, with membrane extensions driven by small GTPases
Rac and Cdc42. However, the CR3-mediated phagocytic response
to iC3b-coated targets is boosted by the participation of additional
receptors such as toll-like receptors (TLRs) recognizing pathogen
patterns.
Indeed, it is worth noting that CR3 and CR4 induce phagocyto-
sis mainly in conjunction with stimuli, such as pro-inflammatory
cytokines, which activate phagocytic cells (56). These stimuli
induce an inside-out signaling, which switches integrins to an
active conformation with a higher affinity for iC3b and ICAM-1
(53). This may represent a control mechanism to avoid unwanted
responses to host cells passively coated with a few iC3b molecules
resulting from the continuous low-grade activation of the AP.
Apart from CR3 and CR4, some resident macrophages such as
liver Kupffer cells express CRIg, a receptor for iC3b belonging to
the immunoglobulin family and able to mediate the phagocytosis
of iC3b-coated pathogens (57).
The main consequence of phagocytosis is the elimination
of pathogens. Internalized microorganisms are killed both by
toxic reactive oxygen compounds, generated through a NADPH
oxidase complex assembled at the phagosomal membrane, and
by microbicidal components, such as lysozyme and proteases,
present in phagocyte granules fused with the phagosome to form
the phagolysosome. Finally, CR3-mediated phagocytosis results
in the apoptosis of phagocytic cells, an important step of the
resolution of infection and inflammation (58).
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2576
Merle et al. Complement system part II: role in immunity
Complement in Inflammation
Anaphylatoxins and Their Receptors
Complement anaphylatoxins C3a and C5a play a critical role
in the modulation of immune system activity by complement.
C3a and C5a are the small fragments released after cleavage of
C3 and C5 by the C3 and C5 convertases of the classical and
APs. They contribute to the inflammation and activate immune
cells and non-myeloid cells, which express G-protein coupled
anaphylatoxin receptors C3aR and C5aR (59, 60) (Figure 4).
Anaphylatoxins stimulate inflammation by inducing an oxida-
tive burst in macrophages (61), eosinophils (62), and neutrophils
(63). Moreover, C3a and C5a induce histamine production by
basophils (64) andmast cells (65), resulting in vasodilatation. Even
if pro-inflammatory effects of C3a are not in question, studies
highlight the anti-inflammatory role of C3a in different contexts
(66). Neutrophil migration and degranulation are prevented by
the presence of C3a, whether others granulocytes are activated
by this anaphylatoxin (63, 67, 68). Thus, this suggests an anti-
inflammatory role in acute phase of inflammation, and in cases of
ischemia–reperfusion injury and in sepsis mouse models (69, 70).
The activation product of C4, C4a, seems also to have a
functional activity on macrophages and monocytes (71, 72).
Nevertheless, no C4a receptor has been reported, making it dif-
ficult to ascertain the physiological role of C4a (73). More studies
are needed to understand whether C4a is an anapylatoxin and
what is its mode of action.
In plasma, C3a and C5a are quickly converted by carboxypep-
tidase N and carboxypeptidase B into C3a-desArg and C5a-
desArg, by cleavage of the C-terminal arginine (74–76). Recent
study determined a central role of C3a in carboxypeptidase B2
(CBP2) negative mice, which are unable to convert C3a and C5a
to C3a-desArg and C5a desArg (77). Using a treatment with
blocking antibody against C3aR or C5aR, mice with only a func-
tional C3a/C3aR axis present better survival after sepsis induction,
whereas mice with only a functional C5a/C5aR axis present a less
survival compare to wild-type mice. These data demonstrate two
opposite effects between C3a and C5a, highlighting the complex
role of C3a depending on the context. Another particularity of C3a
and C5a is that C3a-desArg loses its ability to bind to C3aR and
C5a-desArg has 90%weaker pro-inflammatory activity compared
to C5a, as shown in human astrocyte model (78). By contrast,
murine C5a-desArg is as potent as murine C5a upon binding
to C5aR on murine cells (79). These inter-species differences
have to be taken into account when in vivo experiments are
analyzed.
FIGURE 4 | Role of anaphylatoxins C3a and C5a. Anaphylatoxins C3a and
C5a participate in inflammation by interacting and activating immune cells via
C3aR and C5aR, respectively. C3a is implicated in the adaptive immunity by
inducing monoclonal response from B cells and up-regulation of pro-
inflammatory cytokines. Moreover, C3a facilitates the contraction phase of T cells
by increasing IL-10 synthesis. C5a is implicated in Th1 expansion to improve
adaptive immunity response, and allows C5aR internalization in presence of
C5L2 to induce ERK signalization and pro-inflammatory effect of macrophages.
Both are chemoattractant molecule, and allow mast cells migration for C3a,
basophils, macrophages, neutrophils, and lymphocytes recruitment for C5a at
the inflammatory site. Nevertheless, C3a has an anti-inflammatory effect on
neutrophils by inhibiting their degranulation and recruitment.
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Human C3a specifically binds its receptor C3aR (80), whereas
C3a-desArg and C5a cannot bind to this receptor (81). C3aR
belongs to the G-protein coupled receptor (GPCR) family with
seven transmembrane domains. C3a binding leads to transduc-
tion of intracellular signals via heterotrimeric G-proteins and
phosphorylation of PI3K, Akt, and mitogen-activated protein
kinase (MAPK), leading to chemokine synthesis in human (82).
Moreover, in human mast cells, C3a plays a role of chemoattrac-
tant molecule and can play an important role in hypersensitivity
and inflammatory process (83). In case of chronic inflammation,
C3a has pro-inflammatory activity and contributes to disease
progression (60). In human monocytes and monocyte-derived
macrophages, C3aR and TLR-4 costimulation induce the produc-
tion of pro-inflammatory mediators, such as IL-1β, tumor necro-
sis factor alpha (TNF-α), IL-6, and PGE2 (84, 85). Contrary to
these pro-inflammatory functions, in acute inflammation condi-
tions C3a prevents mobilization and degranulation of neutrophils
(66, 68). The difference in the response of inflamed tissues to C3a,
between the acute and chronic phases of inflammation, may well
be due to the differing cell types involved (e.g., neutrophils versus
monocyte/macrophages) (66).
C3a modulates also the responses of the cells of the adaptive
immunity. Human C3a has been described to regulate B cell
function by suppressing the polyclonal immune response, IL-6
and TNFα release, in a dose-dependent manner (86). Mice C3aR
signaling on DCs is important for the generation of Th1 cells (28,
87). A lack of C3aR activation on DC induces a Th2 polariza-
tion and favors the emergence of Treg. C3aR is also expressed
on adaptive immune cells, such as T lymphocytes. Indeed, the
importance of C3aR and C5aR expression for Th1 induction has
been demonstrated in mice (27, 88, 89). Moreover, C3 deficiency
induced a decreased expression, on T cells, of the α and β chains
of the IL2 receptor. This may explain the aberrant Th1 response
observed in patients with C3 deficiency. C3a also participates in
the contraction phase of Th1 by regulating IL-10 expression (88).
C3aR is expressed not only by the immune cells but also by
endothelial and epithelial cells. Stimulation of C3aR on endothe-
lial cells induces a rapid mobilization of intracellular granules,
Weibel–Palade bodies, containing von Willebrand factor and
P-selectin. Hence, the cell acquire a pro-inflammatory and pro-
thrombotic phenotype, since P-selectin helps the recruitment of
leukocytes via binding to PSGL-1 (90) and von Willebrand factor
mediates platelet adhesion (91). Moreover, human and mouse
P-selectin binds to C3b on cell surfaces and serves as a platform
for the formation of C3 convertases and the activation of the AP
(92, 93). C3a activation of endothelial cells thus forms an ampli-
fication loop of complement activation, implicated in microvas-
cular thrombosis, including in a mouse model of Shiga-toxin
(Stx2)/LPS induced hemolytic uremic syndrome (HUS) (93).
Human and mouse C5a bind to C5aR, which also belongs also
to the GPCR family (94). C5aR stimulation induces downstream
effect such as activation of PI3K-γ (95, 96), phospholipase Cβ2
(97), phospholipase D (98), and Raf-1/B-Raf-mediated activation
of MEK-1 (99). C5a is known to be a powerful chemoattractant
molecule and plays a critical role in the inflammatory response
by recruiting immune cells such as macrophages (100), neu-
trophils (101), basophils (102), and myeloid-derived suppressor
cells (MDSCs) (103). Human C5a also recruits adaptive immune
cells, such as T cells, which express constitutively C5aR on their
surface (104). Human B cells express C5aR but respond to C5a
only in case of activation (105). In a CD55 /  mouse model, it
has been demonstrated that C5a production by APC is essential
for differentiation of T cell in Th1 effector cells (106). Indeed,
addition of C5a on CD80 / , CD86 / , and CD40 /  APC
restored T cell activation, providing a link between GPCR, cos-
timulation signals via CD28 and T cell survival (27). The axis
C5a/C5aR appears to have a crucial role in sepsis, based on the
observation that the inhibition of C5a/C5aR interaction decreased
the mortality in a rat model (107). Another function of C5a is
to induce vascular endothelial growth factor (VEGF) expression
and to promote angiogenesis in a human retinal model (108).
In a model of enteric infection, C5a is generated thanks to the
stabilization of the APC3 convertase by properdin and leads to IL-
6 release from colonic epithelial cells (109). Then, IL-6 regulates
inflammation induced by bacteria. In properdin deficient mice,
the C5a-dependent IL-6 production is impaired, aggravating the
infection. This provides evidences of the implication of C5a in the
defense against bacteria-triggered epithelial injury.
C3a, C5a, and C5a desArg are also able to bindC5L2. In human,
C3a-desArg is able to bind C5L2 and regulates triglyceride syn-
thesis rate (110). C5a has a lower affinity for C5L2, as compared
to C5a desArg in human basophil cell lineage (111). As C5a-
and C3a-receptors, C5L2 is composed by seven transmembrane
domains but it is not coupled with G protein (112). Previous work
on human neutrophil determined a role of C5L2 as a negative
regulator of anaphylatoxin receptor activity after activation and
interaction with β-arrestin, this was confirmed in mouse model
(113, 114). However, its role remains unclear. C5L2 has been
described as an anti-inflammatory receptor, because C5L2 / 
mice have increased production of pro-inflammatory cytokines
IL-6 and TNF-α (115). Nevertheless, deficiency of C5L2 on
macrophages, neutrophils, and fibroblasts decreased their proin-
flammatory capacity in vitro. C5L2 is also essential for the C5a-
mediated cell infiltration in in vivo, in a mouse model, suggesting
a role of positive modulator of C5a-induced responses (67).
C5L2 expression in human atherosclerosis lesions is corre-
lated with an increase of IL-1β and TNF-α release, supporting
the pro-inflammatory effect of C5L2 (116). It has recently been
reported that human C5L2 and C5aR are able to form a het-
erodimer (117). This complex induces internalization of C5aR
upon C5a binding and promotes ERK and MEK signaling in
a mouse model of acute experimental colitis (118). This inter-
nalization of GPCR has already been demonstrated in in vitro
assays as essential for the induction of the late stage of ERK
signaling (119, 120).
Crosstalk Between C3aR and C5aR Signaling
Pathways with Toll-Like Receptor Signaling
C3a and C5a are able to induce potent inflammatory pathways
via their receptors C3aR and C5aR. The implication of interme-
diates such as NF-kB, MAPK, and c-Jun N-terminal kinase (JNK)
in their transduction pathways suggests a potential crosstalk
with other pathways, such as those of TLRs. Indeed, comple-
ment is involved in TLR-induced inflammation (121) (Figure 5).
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FIGURE 5 | Crosstalk between complement and TLR pathways.
C5a/C5aR signaling pathway can cooperate with TLR-4 activation by
LPS on macrophages. Intermediate signaling pathways JNK and MAPK
are activated and thus lead to pro-inflammatory effect by TNF-α, IL6,
and IL1-β synthesis. On dendritic cells (DCs), TLR-4 and C5aR
cooperate in different manner between mice and human. In vivo
experiments have demonstrated an implication in Th1 cells expansion,
whereas in human, an anti-inflammatory role of TLR-4/C5aR
collaboration has been described by an antagonized effect on IL-12
and IL-23 synthesis by DC.
Co-activation of MyD88-dependent TLRs (TLR-2, TLR-4, and
TLR-9) and complement in CD55 /  knockout mice increased
plasma inflammatory cytokines such as IL-6, TNF-α, and IL-
1beta. Moreover, complement activation by the fluid phase cobra
venom factor (CVF) synergizes with LPS to cause a dramatic
increase of IL-6 production. These results suggest a strong interac-
tion between TLRs and complement signaling in vivo to promote
inflammation and modulate adaptive immunity (121). Comple-
mentmay interact with TLR signaling by C3aR andC5aR, because
of the involvement ofMAPK, extracellular signal-regulated kinase
(ERK1/2), and the JNK, but not p38 MAPK (121). TLR2 also
crosstalks with CR3, since TLR2 can transactivate CR3 via PI3K
by an inside-out signal (122). In turn, CR3 can regulate TLR2
signalization by recruiting TIRAP and facilitating the recruitment
of MyD88 signaling adaptor to initiate TLR signaling (123). Sev-
eral studies have shown a crosstalk between complement and
TLR-4. It is known that TLR-4 activation by LPS can induce C5aR
up-regulation on hepatocytes mediated by IL-6 (124). Another,
immune-modulatory function of C5a is to reduce the production
of IL-12 family cytokines by mouse inflammatory macrophages
stimulated by TLR-4 ligands (125). In turn, this resulted in regula-
tion of Th1 cells polarization and a limitation of their expansion.
A synergy between C5a and TLR ligands on mouse DC stimu-
lation was found upon stimulation of these cells with a fusion
protein composed of C5a and an endogenous ligand for TLR-4
(extra domain A) and an antigen (126). This induced strong
antigen-specific T cell responses in vivo, without production of
immunosuppressive molecules. In humans, the C5a-mediated
immature DC stimulation appears more complex. C5a increases
the cytokines production in immature DCs, but upon TLR-4
stimulation, C5a inhibits the production of IL-12, IL-23, and
TNFα, thus having an anti-inflammatory role (127). These results
emphasize that the effects of anaphylatoxins on immune response
depend on the crosstalk not only with TLRs but also with other
receptors.
Complement and Adaptive Immunity
Discoveries over five decades have shown that the complement
system plays an important role not only in the inflammation but
also in the adaptive immunity.
The Complement System and Its Interplay with
B Cells
The relationship between complement and B cells has already
been demonstrated 40 years ago in vitro and using in vivo mod-
els. C3 plays important role in antibody generation by B cells
(Figure 6). In case of C3 depletion [by a structural analog of C3
from snake venom (CVF), which is capable to bind to FB and
to activate complement in fluid phase], the humoral immunity
toward certain thymus-dependent antigens and the lymphocyte
cooperation was impaired (128, 129). These and other early stud-
ies demonstrated that complement binds and localizes foreign
antigens within sites where the lymphocytes response takes place.
B cells express complement receptor CR2 (CD21), which interacts
with C3d and iC3b on the surface of the antigen and forms
also a co-receptor complex with CD19 and CD81 (130). Thus,
the complex C3d:CR2 induces an increase of B cell receptor
(BCR) signaling in the presence of C3d-opsonized antigen on
B cell surface (131). In vivo, C3 is required for the induction
and maintenance of memory cells of the B cell lineage within
the microenvironment of germinal centers (GCs), where B cells
encounter antigen–antibody–C3 complexes on the surfaces of fol-
licular dendritic cells (FDCs) (132).WhenC3d-opsonized antigen
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FIGURE 6 | Complement receptors implication in adaptive immunity.
CR2 activation by interaction with C3d-opsonized antigen on follicular dendritic
cells increases CMH expression and allows antigen presentation to TCR. Then,
costimulatory molecules are expressed and T lymphocytes help in memory B
cells maturation in germinal centers. Moreover, C3d/CR2 interaction lowers the
activation threshold of B cells and increases BCR signaling activity. Cumulated,
C3d/CR2 interaction induces specific IgG generation by B cells, and C3d works
as a natural adjuvant. CR3 and CR4, expressed on immune cells.
binds to CR2 on FDCs, they can present the antigen in the GC
and induce effector and memory B cells (133). This underlines
the importance of CR2 expression on FDCs and B cell surface for
the generation of antigen-specific IgG. C3d serves as a molecular
adjuvant by lowering the threshold for B cell activation by 1000 to
10,000 times (134).
The human complement regulator of the CP C4b binding
protein (C4BP) has functions extending beyond the dissoci-
ation of the classical C3 convertase and serving as cofactor
for FI for C4b inactivation. It binds directly to the costimu-
latory protein CD40 on human B cells at a site that differs
from that used by the CD40 ligand. C4BP induces prolifer-
ation, the up-regulation of CD54 and CD86 expressions, and
IL4-dependent IgE isotype switching in normal B cells. These
observations suggest that C4BP is an activating ligand for CD40
and establish another interface between complement and B cell
activation (135).
The auto-reactivity of B cell is also tightly regulated by com-
plement. C4 has been demonstrated to be essential to maintain
peripheral B cell tolerance (136). Deficiency in C4 promotes the
emergence of autoreactive B cells during the maturation in the
GCs. These results could be explained by a lack in the clearance
of apoptotic cells in GCs that leads to an impairment in host
antigen presentation by APC, essential for the education and the
peripheral B cell tolerance.
The complement system can contribute to autoimmune dis-
eases by decreasing the threshold for B cell activation. For
example, in a collagen-induced arthritis (CIA) mouse model,
C3 depletion delays and decreases severity of the disease (137).
Complement via C3d plays a key role in B cell function, and C3d
antigen can break anergy in autoreactive B cells (138). Comple-
ment can modify the antigen-specific B cell response in exper-
imental autoimmune encephalomyelitis (EAE) and possibly in
multiple sclerosis (MS). In EAE mouse model, consumption of
complement, using CVF, significantly attenuates clinical and his-
tological EAE (139). The authors suggest that complement breaks
the anergy of autoreactive B cells, leading to autoantigen-specific
IgGproduction, while the total IgG response remained unaffected.
The Complement System and Its Interplay with
T Cells
The importance of complement for the survival of resting T cells
has been described above. Upon infection with a pathogen, T
cell proliferation and differentiation are controlled by APC and
their microenvironment. Complement is able to polarize T cells
and participates to the induction and effector phase, as well as to
the contraction phase of the T cell response (140–142). In fact,
during inflammation, anaphylatoxins C3a and C5a are able to
bind their corresponding receptors expressed on the T cells and
APC surface, leading to cytokine production by these cells (27)
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FIGURE 7 | Local synthesis of C3 by antigen presenting cells
(APC) is implicated in antigen-specific T cell response. C3
synthesis by APC in case of pathogen internalization induces late
apoptotic cargo and allows high expression of MHC on APC surface.
Thus, it participates in antigen-specific T cell proliferation and Th1
generation. Local C3 and C5 generate C3a and C5a, which induce
up-regulation of Bcl-2 and down-regulation of FAS expression via C3aR
and C5aR to facilitate T cell proliferation. Moreover, C3a/C3aR and
C5a/C5aR signaling pathways activation promotes Th1 generation and
avoid Treg differentiation.
(Figure 7). Local C3 synthesis by DC is necessary to induce T cell
activation and Th1 response (28). C3 deficiency was shown to
accelerate the fusion of the apoptotic cargowith lysosomes and led
to impaired antigen-specific T cell proliferation in vitro and in vivo
(143). Moreover, C3a/C3aR is responsible for up-regulation of
the anti-apoptotic Bcl2 and down-regulation of the pro-apoptotic
molecule FAS during infection on myeloid and lymphoid cells,
inducing immune cells survival and proliferation (144). The
absence of C3aR and C5aR stimulation during T cell activation
induces Treg development (145, 146). Thus, C3-deficient patients,
who cannot produce C3a and C3b, present a lack of Th1 response
whereas Th2 response remains normal (147, 148).
The complement regulator CD46 plays an important role in the
regulation of T cells (149) (Figure 8). CD46 has different isoforms
affecting its cytoplasmic tail and resulting from alternative splic-
ing. Different isoforms are expressed in different organs. CD46
engagement on CD4+ T cells promotes the effector potential of
Th1 cells (150). As IL-2 accumulates, it switches cells toward a
regulatory phenotype, attenuating IL-2 production and upregu-
lating IL-10. The interaction of the CD46 cytoplasmic tail with
the serine–threonine kinase SPAK plays an important role in this
process. The γδ T cells express an alternative CD46 isoform and
thus are unable to switch from IL2 to IL10 production. The Treg
express differentCD46 cytoplasmic tails, as compared toTh1 cells.
Therefore, CD46 uses distinct mechanisms to regulate different
T cell subsets during an immune response. Recently, the Notch
family member Jagged1, which is expressed on T cells, has been
identified as a new natural ligand of CD46 (147). Jagged1 binds
Notch-1 and this interaction is responsible for cellular activation
and proliferation. The cis interaction (on the same cell) of CD46
and Jagged1 leads to a competition with Notch, thus controlling
the homeostasis of naïve T cells and inhibiting their activation.
In the case of TCR stimulation, CD46 is down-regulated, which
allows Notch-1 and Jagged1 to bind in cis and in trans (from two
different cells). This induces Th1 proliferation and polarization,
leading to IFN-γ and IL2 induction. Interestingly, CD46-deficient
patients are unable to produce IFN-γ and have a lack of Th1
response, whereas Th2 response remains normal. Taken together,
these results suggest that the expression of CD46 is necessary
to induce a Th1 response. Then, CD46 plays a negative feed-
back when proliferation leads to T cell/T cell contact limiting
the expansion of Th1 cells and allows a contraction phase. The
binding site for Jagged1 on CD46 has beenmapped to the first two
CCP domains (147). There is no overlap between this binding site
and the C3b binding site, which is located in the CCP3 and 4.
CD55 (decay accelerating factor, DAF) also plays a role in the
establishment of the adaptive immune response. In addition to
control complement activation, experiments on CD55 deficient
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FIGURE 8 | T cell response is modulated by complement components.
MHC/TCR interaction between APC and T cell decrease CD46 expression on T
cell and allows cis interaction between jagged1 and Notch-1 on T cell surface to
promote T cell proliferation, IL-2, and IFN-γ production. Thereafter, trans
interaction between jagged1 and Notch-1, and CD46 work as negative
feedback to control T cell homeostasis. Soluble C5b–9 and CR1 regulate T cell
activation. Interaction between soluble form of C5b–9 and its specific inhibitor
CD59 on T cells decrease TCR re-expression after its internalization to limit T
cell activation by transmitting a signal via Lck. CR1 activation by iC3b decreases
IL-2 synthesis and proliferation of T cell to promote a negative feedback of T cell
activation. CD55 engagement on T cells negatively regulates Th1 induction cells
by inhibiting IFN-γ production. Intracellular C3 in T cell is cleaved by CTSL and
promotes C3b and C3a intracellular generation. Interaction between C3a and
C3aR induces mTOR signaling and survival signal of the immune cell.
mice showed an enhanced Th1 response with a hypersecretion
of IFN-γ (151, 152). This may be explained by the overactivation
of complement leading to strong local anaphylatoxin produc-
tion (153).
CD35 and CD59 also participate in T cell regulation. Recent
study showed that CD59 is able to modulate T cell activation
by transmitting a signal via Lck to TCR/CD3ζ. A knock-down
of Lck accelerated the re-expression of CD3 at the cell surface
(154). Engagement of CD35 (CR1) on T cells reduces their rate
of proliferation and IL-2 secretion (155). Reduction of the expres-
sion of CD46 on activated T cells may lead to local complement
overactivation, thus generating larger amount of C3b, iC3b, and
C5b–9. Therefore, binding of C3b and iC3b to CD35 and C5b–9
toCD59 could contribute to the negative feedback controlling Th1
expansion (149).
In addition, intracellular mechanisms of sensing C3b-
opsonized pathogens have recently been described (156).
Pathogens that cross the cell membrane, with covalently attached
complement C3 on their surface, activate mitochondrial antiviral
signaling. This mechanism would represent an autonomous
immunity of the cells against non-enveloped viruses and cytosolic
bacteria, by inducing signaling pathways, such as NF-kB,
IRF3/5/7, and AP-1, leading to pro-inflammatory cytokines
production (156).
All these examples illustrate the importance of complement for
the mounting of a successful immune response. Therefore, this
cascade should not only be considered simply as a humoral factor,
mediating innate immunity and inflammation, but also as a potent
regulator of cells functions in the adaptive immunity.
Strategies of the Pathogens to Evade
the Complement System
Complement system works as a first line of defense and allows
in many cases to avoid infections. Nevertheless, the evolution of
the pathogens resulted in elaboration of evasion strategies against
complement attack. These mechanisms of complement evasion
can be classified in different groups (157) (Figure 9).
Binding of Host Complement Regulators
Binding of host complement regulators on their membrane allows
pathogens to inactivate complement. Bacteria, viruses, fungi, and
parasites have been shown to bind high levels of efficient com-
plement regulators such as FH, factor H-like 1 (CFHL-1), and C4
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FIGURE 9 | Pathogens are able to protect themselves from
complement activation. Pathogens have developed different strategies
to inhibit complement activation. They can be classified in four different
groups. Several pathogens are able to bind regulators of complement
activation (RCA), such as FH and C4BP, to decrease C3 deposition.
RCA-like expression allows pathogens to block complement activation
without the need to recruit complement regulator. Synthesis of proteases
specifically against complement proteins degrades complement
components. The last group is pathogens able to express C3 convertase
inhibitors.
binding protein (C4BP) (158). Recruitment of these regulators can
accelerate the decay of the C3 convertase and provide cofactors
for FI, which cleaves C4b and C3b, thus protecting the pathogen
against complement attack.
To bind fluid phase complement regulators, pathogens express
specific molecular platforms with high affinity, such as PorA in
Neisseria meningitidis (159), filamentous hemagglutinin in Bor-
detella pertussis (160), Ail in Yersinia pseudotuberculosis (161),
factor H binding protein (fHbp) and neisserial surface protein A
(NspA) in N. meningitidis (162), and M protein family in group A
streptococci (163).
Factor H binds to pathogens by a “common microbial binding
site,” located in its C-terminal domain CCP20. This domain binds
to heparin and other GAGs on the host cell surface, but the
binding sites for GAG and for pathogens surface proteins are
not identical (164, 165). Three key amino acids (R1182, R1203,
R1206) are critical for this “common microbial binding site” for
at least seven Gram-negative and Gram-positive pathogens (165).
In addition, the microbial proteins enhanced binding of FH19–20
to C3b, forming a triple complex, and leading to a more efficient
complement inactivation on the pathogen surface. This is a unique
example of convergent evolution, resulting in enhanced immune
evasion of important pathogens via utilization of a “superevasion
site” (165).
In addition to CCP 19–20, pathogens trap FH by binding to
CCP6–8. Neisseria species bind this region of FH. Por1A from
Neisseria gonorrhoeae, interacts with CCP 6, in addition to CCP
19–20, to escape from complement attack (166). Also, fHbp and
NspA from N. meningitidis can recruit FH by binding to CCP
6–7 (162, 167). Study of the structure of fHbp by mutagenesis
revealed that fHbp binding site for CCP 6–7 overlaps with sucrose
octasulfate, a GAG analog. FhbB from Treponema denticola binds
FH by a similarmechanism. Study of FH/FhbB interaction by site-
directed mutagenesis revealed a binding site localized in CCP7 of
FH (168).
Staphylococcus aureus has developed a different strategy to
prevent complement initiation. Staphylococcal protein A (SpA)
recognizes the Fc portion of Igs with high affinity and hide the
binding site for C1q, thus blocking the initiation of the CP (169).
The outermembrane protein SdrE binds FHandC4BP to S. aureus
(170, 171). Together, these findings suggest that S. aureus is able
to inhibit the three complement pathways.
Expression of Complement Regulators-Like
Proteins
Expression of complement regulators-like proteins can contribute
to pathogens camouflage. Some viruses, such as poxvirus, have
found ways to produce soluble proteins that closely mimic the
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structure and function of host regulators, such as vaccinia virus,
which produce VCP, a protein similar to CD55 and MCP. Thus,
these viruses inhibit both CP and AP, dissociating C3 convertases
formed on C3b and C4b. Monkeypox virus produces a com-
plement regulator-like protein, MOPICE, which is able to bind
human C3b and C4b and serves as cofactor for FI (172). MOPICE
is considered as a virulence factor of this virus, since it is expressed
in the more virulent strains from Central Africa and absent in
the less virulent pathogens fromWest Africa. Another example of
complement regulators-like activity comes from Herpes viruses,
which express transmembrane gC1 and gC2 glycoproteins able
to bind C3b and to specifically accelerate the decay of the AP
C3 convertase (173). Borrelia burgdorferi produces a CD59-like
protein, which has affinity for C8b and C9 and avoids MAC
formation (157).
Production of Proteases that Degrade
Complement
Production of proteases that degrade complement proteins is
frequently observed in bacteria. Indeed, Pseudomonas produce
Pseudomonas elastase (PaE) and alkaline protease (PaAP) that
cleaves immunoglobulins and C1q, thus preventing activation
of the CP (174). In addition, these proteases are able to inacti-
vate C3 into a non-functional fragment and inhibit complement
activation (174). Leptospira strains are able to cleave directly
complement proteins and inhibit the three complement path-
ways. Leptospira produced metalloproteases may not only cleave
C3 but also FB, C4, and C2 (175). Generated C3 degradation
products differ from those obtained by FI, suggesting that they
would not result in opsonization and phagocytosis. S. aureus is
also able to produce distinct proteolytic enzymes against com-
plement proteins. Staphylokinase can form a complex with plas-
minogen, resulting in a serine protease activity efficient against
C3 and IgG. Moreover, plasmin is able to bind the surface of
S. aureus and inhibits the binding of IgG, C3b, and iC3b and
blocks the effect of opsonization (176). This enzyme activity
leads to the CP inhibition. S. aureus produces four important
proteases: cysteine proteases staphopain A and B, serine pro-
tease V8, and metalloproteinase Aur. These proteases lead to
a drastic decrease in the hemolytic activity of serum and are
efficient against the three pathways (177). Aur is responsible for
the consumption of C3 in the fluid phase (178). N. meningitidis
is able to produce a protease NalP, which cleaves C3. This degra-
dation produces two fragments, a shorter C3a-like and a longer
C3b-like, degraded by host serum and leading to a decreased
C3b deposition on the bacterial surface (179). N. meningitidis
is able to inhibit the CP by capsular oligosaccharides, which
represents a virulence factor of meningococcal infections (180).
Capsular oligosaccharides interfere with engagement of C1q by
IgG Fc, and lead to decreased C4b deposition and inhibition of
CP activation.
Viruses can also produce C3b cleaving enzymes. Nipah virus
particles carry a FI-like protease activity able to cleave and inac-
tivate C3b, using FH and CR1, but not CD46, as cofactors (181).
These data help to explain how an enveloped virus such as Nipah
virus can infect and disseminate through body fluids that are rich
in complement.
Production of Inhibitors of C3 Convertase
Production of inhibitors of C3 convertase has been observed in
a few cases. S. aureus produces extracellular fibrinogen-binding
protein (Efb), which inhibits the conversion of C3 to C3b by its
affinity for the thioesther domain (TED). It binds to the TED
domain on an area, shared by FH and CR2 binding sites (182–
185). Efb acts as a C3 convertase inhibitor by blocking C3b forma-
tion and inhibits the opsonophagocytosis by granulocytes (186).
Ehp (also known as Ecb), a homologous protein of Efb, binds
two molecules of C3b and works as an efficient inhibitor of the
alternative C3 convertase (187). Thus, it leads to a decrease of
the activation of the C5 convertase and of the resulting C5a level.
Surface immunoglobulin-binding protein (Sbi) forms a tripartite
complex with C3b and functional FH that potentiates inhibition
of complement activation (188). Efb and Sbi are able to recruit
humanplasminogen after binding toC3/C3b. Plasminogen is con-
verted to plasmin by bacterial staphylokinase or by host-specific
urokinase-type plasminogen activator and degrades C3 and C3b
in the local microenvironment, thus protecting S. aureus (184,
189). Of note, the tripartite complex formed by C3, plasminogen,
and Efb-C is more efficient than the one with Sbi, probably due
to the higher affinity of C3d to Efb than Sbi, (184). The action of
these molecules prevents the activity of the C3 and C5, as shown
by a decreased C5a generation (190).
Contrary to Efb, staphylococcal complement inhibitor family
(SCIN-A, SCIN-B, SCIN-C), can bind C3b in two distinct regions
with a primary site at domainMG8 (191–194). By competing with
FB and FH, SCIN is able to block the formation of alternative
C3 convertase on one side, and to block the generation of iC3b
that could induce phagocytosis on the other side. Moreover, SCIN
binds and stabilizes the C3 convertase C3bBb, blocks the decay
acceleration, and inhibits the cleavage of C3 into C3b. Thus,
it avoids opsonization and complement activation in the same
time (193).
Targeting binding sites for complement inhibitors on bacte-
rial surfaces and complement-degrading proteases with vaccine-
induced antibodies may be used as a strategy for novel vaccines
designed to prevent complement escape. On the other hand,
some bacterial proteins with anti-complement activity, such as Efb
and SCIN, represent potential novel therapeutics, able to control
undesired complement activation and tissue injury in multiple
non-infectious diseases (195, 196). It is important to consider that
by blocking C3 convertase formation, these inhibitors will avoid
opsonophagocytosis and, by such, increase the risk of infection
in treated patients (197). The increasing knowledge of the com-
plement evasion strategies of pathogens provides novel insights
for more efficient vaccine development and for designing novel
therapeutic complement inhibitors.
Complement and Non-Infectious Diseases
The importance of the complement system in physiology is illus-
trated by severe and life threatening diseases, occurring in case of
inefficient or exuberant complement activity (Figure 10). Abnor-
mal complement activity is associated with a large number of
inflammatory, autoimmune, thrombotic, and age-related diseases.
The examples of systemic lupus erythematosus (SLE), atypical
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FIGURE 10 | Implication of complement deficiencies in pathologies.
Deficiencies of the components of the CP C1q, C1r, C1s, C2, and C4 are
associated with autoimmunity. Lack of regulators of the AP FH, CD46, and FI
(as well as overactivation of the components of the C3 convertase C3 and FB) is
linked to aHUS and C3G. Deficiencies of the terminal complement components
C5, C6, C7, C8, and C9 as well as of the only positive regulator of
complement – properdin is susceptibility factors to development of
meningococcal meningitis. Lack of expression of the regulators of the C3/C5
convertase CD55 and the terminal pathway CD59 on erythrocytes are a cause
of red cell lysis in paroxysmal nocturnal hemoglobinuria (PNH).
hemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3G),
age-related macular degeneration (AMD), and cancer are treated
here in more details, but these are just few among a large list of
diseases, including also the paroxysmal nocturnal hemoglobinuria
(PNH), graft rejection after transplantation, ischemia/reperfusion
injury, Alzheimer and Parkinson diseases, etc.
Diseases Associated with Deficient
Complement Activation
Systemic Lupus Erythematosus
Deficiency of components of the classical complement pathway
C1q, C1r, C1s, and C4 are very rare but are strongly associated
with autoimmune manifestations. The autoimmune disease SLE
is characterized by symptoms ranging from skin rashes, chronic
fatigue, and arthritis to the more severe glomerulonephritis,
serositis, and neurological involvement (198). C1q is the strongest
genetic susceptibility factor for SLE, since over 90% of the individ-
uals homozygous for mutations in this protein develop lupus-like
symptoms (199). The mutations can cause quantitative deficiency
(199) or functional abnormalities (13). A functional abnormality
of C1q, due to amutation in the C1r2C1s2 binding site, resulted in
an inability of C1 complex formation and presence of free C1q in
the patient serum. The strong association of the mutations of the
CP proteins with autoimmunity can be explained by the “waste
disposal” hypothesis of Walport (17), suggesting that lack of C1q
opsonization and CP activity perturbs the immunologically silent
uptake of apoptotic cells and debris, thus resulting in an immune
response against self-antigens.
Alteration of the function of C1q can be also induced by
presence of autoantibodies against C1q, which are frequently
found in SLE, especially in patients with lupus nephritis (200).
These antibodies bind to the collagenous tail of C1q (201) or
the globular domain (202). These antibodies amplify the effect
of C1q-containing immune complexes in the kidneys (203, 204),
bind to C1q on early-apoptotic cells, and enhance complement
activation (205).
Impaired clearance of apoptotic cells, induced by lack of C1q
or inefficient complement activation due to lack of C1r, C1s, C2,
and C4 are associated with SLE. At the same time, complement
overactivation, due to the presence of anti-C1q antibodies or
complement activating immune complexes in the circulation and
in kidney glomeruli, is also leading to the same disease, albeit by a
different mechanism. Therefore, both lack of activation and a too
strong activation of the CP can be linked to autoimmunity.
Diseases Associated with Complement
Overactivation
Inherited and acquired quantitative and functional deficiency of
the regulators of the alternative complement pathway FH, FI, and
CD46 as well as abnormalities inducing overactivation of the AP
C3 convertase are associated with rare renal diseases like aHUS
(206, 207) and C3G (208, 209).
Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome is a renal thrombotic
microangiopathy disease, characterized by glomerular
microvascular endothelial cells activation and damage, leading to
microthrombi formation andmechanical hemolysis (206).Within
the last decade, complement AP dysregulation has emerged as the
cause of aHUS (207, 210). In this disease, complement induces
glomerular endothelium damage, secondary to unrestricted
complement activation with C5b–9 deposits on the endothelial
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cells surface. A loss of regulation is a result of mutations in FH,
FI, or CD46 genes, found in ~50% of the cases. FH mutations
are frequently located in the C-terminal domains and result in
reduced capacity of FH to bind C3b and the GAG of the cell
membrane (211–213). Mutations in FI impair its catalytic activity
(214, 215). Complement overactivation in 10% of the cases is due
to mutations in the components of the C3 convertase C3 and FB,
forming a more potent convertase and/or a converatase resistant
to decay by the regulators (216–221). In addition to mutations
in complement genes, autoantibodies against FH, leading to an
acquired FH functional deficiency, have been reported in aHUS
patients (222–224). The binding epitopes of these autoantibodies
are localized to the C-terminal recognition region of FH, which
represents a hot spot for aHUS mutations (225).
Altogether complement-associated abnormalities are found in
about 60% of the aHUS patients (226, 227). At present, over
200 distinct mutations have been reported in aHUS patients
(207). All reported mutations were heterozygous, except in 15
patients (mostly from consanguineous families) with homozy-
gous FH or CD46 deficiency (228). In a particular form of
aHUS, mutations were found in DGKE – a gene outside of
complement, involved in the protein kinase C signaling path-
way (229). Its deficiency induces permanent pro-coagulant phe-
notype of the endothelial cells (230). aHUS has an incomplete
penetrance among the mutation carriers and a triggering event
(infection, pregnancy, etc.) and additional genetic predispos-
ing factors (particular at risk haplotypes in FH and CD46) are
needed to induce the disease (220, 231, 232). The hemolysis,
which accompanies the disease onset, can serve as a secondary
hit for the aHUS development, since released heme activates
the alternative complement pathway in the fluid phase and on
the endothelial cells surface (233, 234). The availability of the
first effective anti-complement therapeutic drug, eculizumab,
has changed dramatically the outcome of this rare kidney dis-
ease.
C3 Glomerulopathies
C3 glomerulopathies are rare chronic kidney diseases, character-
ized by predominant C3 deposits in glomeruli, in particular, in
the mesangium and along the glomerular basement membrane,
frequently associated with mesangial cells proliferation. Accord-
ing to the pattern of C3 deposits observed by immunofluorescence
and electronic microscopy, two subtypes of C3G are described –
dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)
(208). The pathogenic process in C3G is presumed to be due
to uncontrolled C3 and/or C5 convertases activation, leading to
C3 deposits and intra-glomerular inflammation. Autoantibodies
targeting the AP C3 convertase, named C3 nephritic factor, are
present in more than 50% of C3G patients (235–237). Few genetic
abnormalities have been identified. These include mutations of
complement genes, coding for C3 (1 case) (238) and the regulator
FH (<20mutations) (237, 239).Mutations affecting FH gene result
more frequently a protein deficiency in the plasma. More recently,
mutations in the CFHR5 gene were reported, as well as rear-
rangements and copy number variations in theCFHR gene cluster
(240–242). A particular form of C3GN is the CFHR5 nephropa-
thy, characterized by a genetic defect in CFHR5, rendering it a
strong competitor of FH. It is found in patients from of Cypriot
descent (241, 243).
InC3G, genetic abnormalities affect the same genes as in aHUS,
with a lesser frequency compared to aHUS, affecting only about
20% of the patients (209, 237). An interesting observation is that
the mutations in FH and in FI, which are associated with C3G,
are frequently the same, as the ones found in aHUS. They induce
either complete or partial FH deficiency or functional defects
in the N-terminal part of the protein (237). Mutations in the
membrane anchoring C-terminal part of FH are found frequently
in aHUS and nearly not in C3G. Therefore, the mutation itself
(particularly the deficiencies of FH and FI and the mutations in
the N-terminal part of FH) may not be sufficient to determine
the type of the renal injury. The triggers of the AP dysregulation
remain undetermined.
C3 nephritic factor and FH or FI mutations, inducing an over-
activation of the AP are found also in patients with another type
of membranoproliferative glomerulonephritis, associated with
immunoglobulin deposits in the kidney – MPGN type I (237).
Therefore, the role of the AP has to be considered even in diseases,
for which CP activation is expected.
Contribution of Complement in Diseases, not
Associated with Complement Defects
Age-Related Macular Degeneration
A particular polymorphism of FH (Y402H) is strongly associated
with development of AMD, which is the first cause of blindness
in the developed countries (244–247). The loss of central vision
is associated with loss of photoreceptors and drusen formation
in the retina (248). This is due to the constant exposure to light,
smoking, the high-metabolic rate in the eye, and its particular sen-
sibility to oxidative stress. Oxidized lipids and malondialdehyde
are generated and if not properly handled by FH, they induce
complement activation (249, 250) (Figure 11). FH binding to
oxidized epitopes on altered or dying cells leads to inactivation of
C3b to an anti-inflammatory fragment iC3b. Moreover, FH atten-
uates malondialdehyde-induced IL-8 production by macrophages
and retinal pigment epithelial cells and decreases the expres-
sion of genes involved in macrophage infiltration, inflammation,
and neovascularization in the eye. At risk, FH variant H402 has
a weaker capacity to interact with oxidized lipids and malon-
dialdehyde in the drusen, thus allowing constant background
complement activation, leading to retinal epithelial cells damage
and macrophages activation (249, 250). These results explain the
strong genetic association of the H402 with the risk of AMD.
Increased risk for AMD is conferred also by polymorphisms
in several other genes of the alternative complement pathway,
including FI, C3, C2/FB, and C9 (251).
Genetic analyses revealed that the deletion of CFHR1 and
CFHR3, which is a polymorphism in the normal population with
varying frequency depending on the ethnicity between 2 and 20%
(252), is a protective factor against development of AMD (253).
CFHR1 and CFHR3 are natural deregulators of FH, competing
with it for cell surface binding (241, 254, 255). Therefore, their
absence will increase the local binding of FH to oxidized surfaces,
leading to a better protection, thus explaining the protective effect
of this deletion in AMD.
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 25716
Merle et al. Complement system part II: role in immunity
FIGURE 11 | Role of factor H Y402H polymorphism in age-related
macular degeneration. FH binds to GAG, oxidized lipids, including
malondialdehyde via CCP7 on the membrane of injured retinal epithelial (RPE)
cells and protects them from complement attack. H402 variant has a weaker
affinity to these products of the oxidative stress and protects less well the cells
surface. Deposited C3b is not inactivated to iC3b and promotes complement
activation. Less iC3b is generated, which contributes to the silent clearance of
the injured cells. RPE cells are activated, secrete pro-inflammatory cytokines,
and activate macrophages in their microenvironment. This chronic inflammation
predisposes to AMD development with aging.
Cancer
Complement has been considered since a long time as an
immune surveillance system against cancer, because comple-
ment is activated on the surface of tumor cells. Nevertheless,
tumor cells develop inhibitory mechanisms for the terminal
steps of the complement cascade, thus preventing complement-
mediated cytotoxicity. Surprisingly, recent studies demonstrated
that complement activation within the tumor microenviron-
ment can promote tumor growth. Complement activation may
support chronic inflammation, promote an immunosuppressive
microenvironment, induce angiogenesis, and activate cancer-
related signaling pathways. The mechanisms of these phenom-
ena are not fully understood. Prolonged complement activation
supports chronic inflammation, promotes an immunosuppressive
microenvironment, induces angiogenesis, and activates cancer-
related signaling pathways.
Several lines of evidence indicate a role for molecules of the
complement system in tumor growth and metastasis, (Figure 12).
C3, C4, or C5aR deficiencies prevent tumor growth in mice,
potentially via inhibition of the CP and the generation of C5a,
which has a potent inflammatory potential. In mouse models, the
presence of C5a in the tumor microenvironment enhances tumor
growth by recruitment of MDSC and increasing T cell-directed
suppressive abilities (103, 256, 257). In a breast cancer model,
C5aR facilitatedmetastasis in the lungs through different immune
mechanisms in the metastatic niche, including the suppression of
effector CD8(+) and CD4(+) T cell responses, the recruitment
of immature myeloid cells and the generation of Tregs and a
Th2-oriented response (258).
Cancer cells also secrete complement proteins that stimulate
tumor growth upon activation via a direct autocrine effect through
C3aR and C5aR signaling (256). In patients with ovarian or lung
cancer, higher tumoral C3 or C5aR mRNA levels were associated
with decreased overall survival. In addition, patients with non-
small cell lung cancer have elevated C5a plasma levels (257).
C3a and C5a seem to have opposing effects during tumor
development and in case of anti-tumor radiotherapy. While C3a
and especially C5a promote tumor growth, radiotherapy-induced
tumor cell death and transient local complement activation with
production of C3a and C5a (259). The latter appeared crucial to
the tumor response to radiotherapy and concomitant stimulation
of tumor-specific immunity.
Overexpression of FH has been described in non-small cell
lung cancer cell lines and on non-small cell lung cancer biopsies
(but not in small cell lung carcinoma and carcinoid cell lines)
(260, 261), in bladder tumor cells (262), in cutaneous squamous
cell carcinoma (cSCC) and cell lines (263), and in hepatocellu-
lar carcinoma tumors (264). Low titer anti-FH antibodies were
also found in sera from patients with non-small cell lung cancer
(265). Recent studies demonstrated that FH binds to pentraxin
3 (PTX3) in the tumor microenvironment, thus preventing local
complement overactivation and generation of pro-tumorigenic
C5a (266). Hence, deficiency of PTX3 accelerated tumor devel-
opment in mouse models of drug-induced cancerogenesis. FI was
also suggested to be associated with tumor development of cSCC
(267). These results provided evidence for a potential role of FH
and FI in the cancer development, but the mechanism of action
are still unknown.
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FIGURE 12 | Role of complement in cancer. Complement plays an
important role in the chronic inflammation and tumor development. Tumor cells
produce complement components and generate C3a, C5a, and C5b–9 in their
microenvironment. This result in autocrine tumor cells stimulation, leading to
proliferation, migration, and invasiveness. C5a stimulates MDSC, which dampen
the immune response, suppressing cytotoxic T cells, and stimulate Treg. C3a,
C5a, and C5b–9 promote angiogenesis, helping in tumor nutrient support and
dissemination.
These examples clearly indicate that complement is indispens-
able immunosurveillance system, which needs to function with
the right force when and where is needed. Therefore, therapeutic
strategies are needed to adjust the level of complement activation
in pathological conditions.
Complement as a Therapeutic Target
Since C1q is produced by the myeloid cells, a bone marrow
transplantation can overcome this deficiency. Such therapy was
efficiently applied to a patient with SLE, resulting in normaliza-
tion of C1q levels and improvement of the clinical status (268).
Deficiency of C1INH in hereditary and autoimmune angioedema
(which is not a complement-mediated disease, but induced by
excessive production of bradykinin, which is a potent vasodilator)
is efficiently treated by plasma derived or recombinant C1INH
(269). Alternatively, missing soluble complement components can
be introduced to the body by plasma exchange. This was success-
fully achieved for C1q (270) as well as for FH and FI deficiency
in aHUS. Plasma therapy was the first line treatment for aHUS
before the development of anti-C5 blocking antibody eculizumab
(271, 272). Eculizumab binds to C5 and prevents its entry into the
C5 convertase, thus blocking completely the generation of C5a
and the formation of MAC (273). This therapeutic is approved
for use in PNH and aHUS and gives excellent results (274, 275).
Currently, clinical trials are ongoing for many different diseases,
where complement is overactivated. Novel inhibitors are under
development to block complement at different levels. Particular
interest is focused on the blockers of complement at the level of
C3 and the C3 convertase. C3b binding peptide compstatin and
its derivatives prevent the entry of C3 into the C3 convertase (276,
277). Plasma derived or recombinant FH and recombinant soluble
CR1 dissociate the alternativeC3 convertase and serve as cofactors
for FI (278). Targeted inhibitors like TT30 (FH CCP1–5:CR2) or
mini FH (CCP1–4:CCP19–20) bring the regulatory N-terminal
domains to the cell membrane, where they are needed to control
complement activation (279–282).
Conclusion
Complement plays a central role in the homeostasis and the
installation of the adaptive innate immune response. By its sup-
porting role in the clearance of apoptotic and necrotic cells, and its
importance in the polarization of T lymphocytes and the humoral
response by the cooperationwith the B-lymphocytes, complement
represents a real keystone of the immune system. This crucial role
for the correct functioning of the organism is illustrated by the
fact that both complement deficiencies and complement overac-
tivation are associated with severe and life threatening diseases.
The improvement of our understanding of the role of complement
in health and disease opens up the possibility to use complement
modulating drugs in the clinical practice.
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